ScreenerHero

AZT ArcticZymes Technologies ASA

OSL · NO · Healthcare · Biotechnology · arcticzymes.com
20.60NOK+3.52%Mkt Cap: 98.35M $P/E: 68.67

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap98.35M USD
Enterprise Value71.58M USD
Revenue (TTM)12.47M USD
Gross Profit10.07M USD
Net Income (TTM)910.29K USD
Revenue/Share2.65 NOK
Last Price20.60 NOK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees50
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010014632
Valuation
P/E (Trailing)68.67
P/E (Forward)37.25
PEG—
EV/EBITDA49.28
EV/Revenue5.74
P/S7.62
P/B2.93
EPS (TTM)0.30
EPS (Forward)0.53
52W Range
18.3018% of range31.40
52W High31.40 NOK
52W Low18.30 NOK
Profitability
Gross Margin95.68%
Oper. Margin15.24%
EBITDA Margin11.65%
Profit Margin8.65%
ROE2.88%
ROA2.70%
Growth
Revenue Growth17.40%
Earnings Growth65.00%
Cash Flow & Leverage
Operating CF2.41M USD
CapEx (TTM)340.45K USD
FCF Margin10.03%
FCF Yield1.27%
Net Debt-23.42M USD
Net Debt/EBITDA-16.12
Balance Sheet
Debt/Equity0.02
Current Ratio17.68
Quick Ratio16.64
Book Value/Sh6.79 NOK
Cash/Share5.27 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 NOK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)28.00 NOK
Upside (mean)+35.9%
Target Range28.00 NOK – 28.00 NOK
# Analysts1
Ownership
Shares Out.51.07M
Float42.17M
Insiders17.41%
Institutions13.81%
Technical
SMA 5020.37 (+1.1%)
SMA 20020.82 (-1.1%)
Beta0.57
S&P 52W Chg14.58%
Avg Vol (30d)25.11K
Avg Vol (10d)29.01K
Technical Indicators
RSI (14)43.3
MACD-0.1114
MACD Signal-0.0097
MACD Hist.-0.1017
BB Upper21.44 NOK
BB Middle20.61 NOK
BB Lower19.77 NOK
BB Width8.08%
ATR (14)0.7629 NOK
Vol Ratio (20d)0.91x